Exocrine Pancreatic Insufficiency Market By Treatment Type (Pancreatic Enzyme Replacement Therapy, Nutritional Supplements, Supportive Care, Emerging Therapies); By Indication (Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Other Indications); By Route of Administration (Oral Administration, Enteral Administration, Combination Therapy); By End User (Hospitals, Specialty Clinics, Home Care, Retail and Specialty Pharmacies); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Exocrine Pancreatic Insufficiency Market Size and How Is the Treatment Landscape Evolving?

The Global Exocrine Pancreatic Insufficiency (EPI) Market was valued at USD 3.00 billion in 2025 and is projected to reach USD 4.77 billion by 2032, expanding at a CAGR of 6.85% during 2026–2032, according to Strategic Market Research. Market growth is driven by increasing awareness, improved diagnosis, rising prevalence of pancreatic disorders, and continued demand for Pancreatic Enzyme Replacement Therapy (PERT).

 

EPI is a condition in which the pancreas does not produce enough digestive enzymes, resulting in poor digestion and nutrient absorption. Common symptoms include steatorrhea (greasy, foul-smelling stools), abdominal discomfort, bloating, unexplained weight loss, and fatigue. Major causes include chronic pancreatitis, cystic fibrosis, pancreatic cancer, and pancreatic surgery.

 

Disease Burden and Key Drivers

• Cystic Fibrosis (CF): A major genetic cause of EPI, affecting more than 70,000 people globally and approximately 35,000–40,000 individuals in the U.S. A high proportion of CF patients develop pancreatic insufficiency early in life.

• Pancreatic Cancer: Approximately 510,000 new cases occur globally each year, with more than 62,000 cases annually in the U.S. Many advanced pancreatic cancer patients experience severe digestive insufficiency.

• Chronic Pancreatitis: The leading adult cause of EPI worldwide, with progressive pancreatic damage frequently resulting in loss of enzyme production.

 

Diagnosis and Treatment

Diagnosis is commonly performed using fecal elastase testing to measure pancreatic enzyme activity, along with blood tests to assess nutritional deficiencies caused by malabsorption.

The standard treatment approach is Pancreatic Enzyme Replacement Therapy (PERT) combined with dietary management and vitamin supplementation. PERT replaces deficient digestive enzymes, including lipase, protease, and amylase, helping improve digestion, nutrient absorption, and patient quality of life.

 

FDA-Approved PERT Therapies

The current EPI treatment market is dominated by prescription pancreatic enzyme products (PEPs), including:

• Creon (AbbVie): Widely used delayed-release enzyme capsules.

• Zenpep (Nestlé Health Science): Available in multiple lipase-strength formulations for individualized dosing.

• Pancreaze: Delayed-release enzyme replacement therapy.

• Pertzye: Bicarbonate-buffered enteric-coated microsphere formulation.

• Viokace: Non-enteric-coated enzyme tablets generally used with acid suppression therapy.

• RELiZORB (Alcresta Therapeutics): Enzyme cartridge system designed for patients receiving enteral tube feeding.

 

Emerging Therapy Landscape

Current innovation focuses on developing non-porcine, recombinant, microbial, and synthetic enzyme therapies to address limitations associated with animal-derived enzymes, supply challenges, and patient acceptance.

Key pipeline developments include:

• MS1819 (Adrulipase): Recombinant microbial lipase derived from Yarrowia lipolytica, investigated for CF and chronic pancreatitis-associated EPI.

• NHS7108: Synthetic enzyme replacement candidate designed as an animal-free alternative with potential dosing advantages.

• Next-generation PERT innovations: Improved formulations and expanded applications of existing enzyme technologies.

 

The EPI market is expected to experience steady growth due to increasing disease recognition, expanding diagnosis rates, and continued reliance on PERT. Future opportunities will be shaped by earlier detection, optimized enzyme replacement therapy, improved nutritional management, and development of next-generation non-animal enzyme solutions.

 

Overall, PERT remains the foundation of EPI management, while emerging recombinant and synthetic therapies represent the next phase of innovation aimed at improving treatment accessibility, patient acceptance, and long-term clinical outcomes.

 

Leaders and Growth Frontiers Shaping Exocrine Pancreatic Insufficiency Market

By Treatment Type

Leading Segment — Pancreatic Enzyme Replacement Therapy (PERT): Pancreatic Enzyme Replacement Therapy dominated the Exocrine Pancreatic Insufficiency Market with approximately 68% share in 2025, representing USD 2.04 billion, and is projected to expand at a CAGR of 6.7% during 2026–2032. Its leadership reflects its established position as the standard treatment for clinically confirmed EPI, with repeated dosing required alongside meals and snacks to replace insufficient pancreatic enzymes. Established pancrelipase products such as Creon, Zenpep, Pancreaze, Pertzye, and Viokace support broad clinical utilization across chronic pancreatitis, cystic fibrosis, pancreatic cancer, and post-pancreatic surgery patients.

Fastest-Growing Segment — Emerging Therapies: Emerging Therapies accounted for approximately 6% of the market, or USD 0.18 billion in 2025, and are projected to record the fastest CAGR of 10.5% during 2026–2032. Growth is supported by development of recombinant and engineered enzyme technologies designed to reduce reliance on porcine-derived enzymes, improve gastric stability, and potentially lower treatment burden. Programs such as Anagram Therapeutics' ANG003 and Nestlé Health Science's NHS7108 illustrate the shift toward next-generation enzyme replacement approaches.

 

By Indication

Leading Segment — Chronic Pancreatitis: Chronic Pancreatitis led the indication segment with approximately 42% market share in 2025, equivalent to USD 1.26 billion, and is projected to expand at a CAGR of 6.4% during 2026–2032. Progressive destruction of pancreatic tissue can result in long-term loss of enzyme-producing capacity, making chronic pancreatitis one of the most established adult pathways into sustained PERT use. The high proportion of patients who develop EPI during prolonged disease further supports recurring treatment utilization.

Fastest-Growing Segment — Cystic Fibrosis: Cystic Fibrosis accounted for approximately 24% of the market, representing USD 0.72 billion in 2025, and is projected to record the fastest CAGR of 7.2%. Pancreatic insufficiency frequently develops early in patients with cystic fibrosis, resulting in long treatment duration and structured management through specialist CF centers. The segment is also becoming strategically important for pipeline innovation, with next-generation enzyme programs initially targeting CF-related EPI.

 

By Route of Administration

Leading Segment — Oral Administration: Oral Administration dominated with approximately 82% market share in 2025, representing USD 2.46 billion, and is projected to expand at a CAGR of 6.5%. Its leadership reflects the widespread use of capsules, delayed-release preparations, tablets, and granules across the major commercial PERT products. Oral administration also fits the meal-based treatment model required for most ambulatory EPI patients.

Fastest-Growing Segment — Combination Therapy: Combination Therapy accounted for approximately 8% of the market, or USD 0.24 billion in 2025, and is projected to record the fastest CAGR of 8.2%. The segment is supported by individualized EPI management in which PERT may be combined with acid suppression, vitamin supplementation, dietary intervention, and nutritional monitoring when enzyme replacement alone does not fully correct symptoms or deficiencies.

 

By End User

Leading Segment — Hospitals: Hospitals accounted for approximately 38% of the market in 2025, representing USD 1.14 billion, and are projected to expand at a CAGR of 6.3%. Their leading position reflects the concentration of EPI identification and treatment initiation around pancreatic surgery, severe pancreatitis, pancreatic cancer, and complex nutritional deterioration, where gastroenterology, oncology, surgery, and dietetic teams are available within the same care pathway.

Fastest-Growing Segment — Home Care: Home Care represented approximately 20% of the market, equivalent to USD 0.60 billion in 2025, and is projected to record the fastest CAGR of 7.6%. Most long-term PERT treatment occurs outside hospitals once patients have been stabilized, while chronic meal-based dosing makes convenient self-administration, refill continuity, and simpler treatment regimens particularly important.

 

By Distribution Channel

Leading Segment — Hospital Pharmacies: Hospital Pharmacies led the distribution channel with approximately 45% market share in 2025, representing USD 1.35 billion, and are projected to expand at a CAGR of 6.2%. Their position is closely tied to specialist treatment initiation following pancreatic surgery, severe pancreatitis, oncology care, and inpatient nutritional management, where PERT may first be prescribed before patients transition to outpatient therapy.

Fastest-Growing Segment — Online Pharmacies: Online Pharmacies accounted for approximately 17% of the market, or USD 0.51 billion in 2025, and are projected to record the fastest CAGR of 8.4%. Their growth reflects the recurring nature of EPI prescriptions, increasing preference for home delivery, digital refill management, and greater convenience for patients requiring continuous enzyme replacement.

 

By Region

Leading Region — North America: North America dominated the Exocrine Pancreatic Insufficiency Market with approximately 39% share in 2025, representing USD 1.17 billion, and is projected to expand at a CAGR of 6.3%. The region benefits from broad availability of established PERT brands, specialist gastroenterology and cystic fibrosis infrastructure, established diagnostic practices, and a sizeable treatment-conversion gap among patients with chronic pancreatitis, pancreatic cancer, and other high-risk conditions.

Fastest-Growing Region — Asia Pacific: Asia Pacific accounted for approximately 21% of the market, representing USD 0.63 billion in 2025, and is projected to record the fastest regional CAGR of 8.0% during 2026–2032. Expansion is supported by improving identification of pancreatic disorders, broader access to gastroenterology specialists, increasing use of enzyme replacement, and expanding treatment availability across countries such as Japan, China, India, and Australia.

 

Innovative Treatment Approaches Shaping the Exocrine Pancreatic Insufficiency Market

Pancreatic Enzyme Replacement Therapy accounted for approximately 68% of the market, representing USD 2.04 billion in 2025, and is projected to expand at a CAGR of approximately 6.7% during 2026–2032. Its position reflects guideline-supported use after EPI diagnosis and recurring administration with meals and snacks. Products from AbbVie, Nestlé Health Science/Aimmune, VIVUS, and Digestive Care provide multiple pancrelipase strengths and formulations that allow physicians to titrate enzyme exposure according to patient requirements.

Emerging Therapies represented approximately 6% of the market, or USD 0.18 billion in 2025, and are projected to record the fastest treatment-type CAGR at 10.5%. The current commercial category includes newer enzyme-delivery and nutritional technologies; investigational products are not counted as existing pharmaceutical sales. Alcresta's RELiZORB represents a differentiated enteral approach, while ANG003 and NHS7108 illustrate the future shift toward recombinant and engineered enzyme platforms.

 

Innovative Advances Shaping the Exocrine Pancreatic Insufficiency Treatment Landscape

Chronic Pancreatitis accounted for approximately 42% of the market, representing USD 1.26 billion in 2025, and is projected to expand at a CAGR of 6.4%. Progressive and often irreversible loss of pancreatic exocrine function supports prolonged PERT utilization, while the high probability of developing EPI after longstanding chronic pancreatitis makes gastroenterology follow-up a major treatment-conversion pathway.

Cystic Fibrosis represented approximately 24% of the market, equivalent to USD 0.72 billion in 2025, with a projected CAGR of 7.2%. The segment has a high treatment intensity because pancreatic insufficiency commonly appears early and patients are managed through structured CF specialist programs. Clinical development by Anagram Therapeutics is also concentrated initially in CF-related EPI, making the indication an important proving ground for lower-pill-burden enzyme replacement.

 

Innovative Administration Pathways Shaping Exocrine Pancreatic Insufficiency Treatment

Oral Administration dominated with approximately 82% share, representing USD 2.46 billion in 2025, and is projected to expand at a CAGR of 6.5%. Capsules, delayed-release beads, granules, and tablets fit routine meal-based enzyme replacement and underpin the major FDA-approved PERT brands. Product differentiation centers on enzyme strength, enteric protection, administration flexibility, and the number of capsules required to achieve an effective dose.

Combination Therapy represented approximately 8% of the market, or USD 0.24 billion in 2025, and is projected to record an 8.2% CAGR. The segment includes enzyme replacement used alongside acid suppression, nutritional supplementation, and individualized dietary intervention. Its role is strongest in patients whose symptoms or nutritional deficiencies persist despite initial enzyme treatment.

 

Innovative Landscape by End User in the Exocrine Pancreatic Insufficiency Market

Hospitals accounted for approximately 38% of the market, representing USD 1.14 billion in 2025, and are projected to expand at a CAGR of 6.3%. Hospitals are important points of treatment initiation after pancreatic resection, severe pancreatitis, cancer diagnosis, and complex nutritional deterioration because these settings bring gastroenterology, surgery, oncology, nutrition, and pharmacy teams together.

Home Care accounted for approximately 20% of the market, or USD 0.60 billion in 2025, and is projected to expand at a CAGR of 7.6%. Once stabilized, patients administer PERT independently with meals and snacks, shifting much of the treatment burden from institutions to the home. Products requiring fewer capsules per meal or simpler dosing instructions could therefore gain a practical advantage in this setting.

 

Innovative Patient Access Pathways Across the EPI Treatment Landscape

Hospital Pharmacies accounted for approximately 45% of the market, representing USD 1.35 billion in 2025, and are projected to expand at a CAGR of 6.2%. Their position is supported by treatment initiation around pancreatic surgery, oncology, severe pancreatitis, and other specialist-managed conditions where EPI is identified during institutional care.

Online Pharmacies accounted for approximately 17% of the market, or USD 0.51 billion in 2025, and are projected to record an 8.4% CAGR. Their relative expansion is linked to refill convenience and home delivery for stable long-term patients, although prescription requirements, payer arrangements, and temperature or storage instructions continue to determine how individual products can be supplied.

 

Regional Opportunities Shaping the Exocrine Pancreatic Insufficiency Market

North America accounted for approximately 39% of the global market, representing USD 1.17 billion in 2025, and is projected to expand at a CAGR of 6.3% during 2026–2032. The region combines an established portfolio of Creon, Zenpep, Pancreaze, Pertzye, and Viokace with substantial treatment headroom: a U.S. database study found that only 58% of identified EPI patients received PERT. Commercial activity from AbbVie, Nestlé Health Science/Aimmune, VIVUS, and Digestive Care therefore operates within a market where brand competition coexists with incomplete treatment conversion.

Asia Pacific accounted for approximately 21% of the market, representing USD 0.63 billion in 2025, and is projected to record the fastest regional CAGR at 8.0%. Chronic pancreatitis prevalence reported across Japan, China, and India provides a substantial disease base, while differences in diagnosis and specialist access create uneven treatment penetration. Australia also illustrates the region's supply challenge, with TGA-listed constraints affecting Creon 25,000 and 35,000 through January 2027.

 

Leading Innovators Shaping the Exocrine Pancreatic Insufficiency Market

The Exocrine Pancreatic Insufficiency Market remains concentrated around established pancreatic enzyme replacement therapy brands, with competition increasingly influenced by enzyme strength, formulation flexibility, physician familiarity, payer access, treatment convenience, and supply continuity. In a recent U.S. survey of 250 healthcare providers experienced in treating EPI, Creon was prescribed by 84.0% of respondents, Zenpep by 60.4%, and Pancreaze by 59.2%, making these the three most frequently prescribed PERT brands in the surveyed population; these percentages represent provider prescribing rates rather than product market shares.

AbbVie — Leading Competitive Company

AbbVie holds one of the strongest established positions in the Exocrine Pancreatic Insufficiency Market through Creon. In the recent U.S. provider study, 84.0% of surveyed clinicians reported prescribing Creon, the highest rate among the evaluated PERT brands. FDA prescribing information confirms that Creon is indicated for EPI in both adult and pediatric patients and is available in five delayed-release strengths containing 3,000, 6,000, 12,000, 24,000, and 36,000 USP units of lipase. This broad strength range supports individualized dosing across infants, children, and adults and across conditions such as cystic fibrosis, chronic pancreatitis, and pancreatectomy. AbbVie's competitive position therefore combines high physician familiarity with flexible meal-based dosing and an established FDA-approved product used across multiple EPI patient groups.

Nestlé Health Science / Aimmune Therapeutics — Leading Competitive Company

Nestlé Health Science, through Aimmune Therapeutics, maintains a broad EPI position through Zenpep and Viokace. Zenpep was prescribed by 60.4% of providers in the recent U.S. survey, placing it second among the evaluated PERT brands. FDA labeling confirms that Zenpep has been approved in the U.S. since 2009 for EPI in adult and pediatric patients and offers eight lipase strengths ranging from 3,000 to 60,000 USP units, providing one of the widest dosing ranges within the branded PERT category. The portfolio is further differentiated by Viokace, a non-enteric-coated pancrelipase tablet indicated with a proton pump inhibitor for adults with EPI caused by chronic pancreatitis or pancreatectomy. This combination gives the company exposure to both broad delayed-release PERT use and a more specialized adult treatment pathway.

VIVUS — Leading Competitive Company

VIVUS represents the third leading competitor based on current U.S. prescribing evidence through Pancreaze, which was prescribed by 59.2% of surveyed healthcare providers. FDA labeling confirms that Pancreaze is indicated for EPI in adult and pediatric patients and is available in six delayed-release strengths ranging from 2,600 to 37,000 USP units of lipase. The lower-strength presentation enables dosing in infants, while higher-strength formulations support older pediatric and adult patients who require greater enzyme exposure. Pancreaze's broad dosing range, established FDA-approved status, and specialty-pharmacy support position VIVUS as an important alternative to Creon and Zenpep, particularly where formulary coverage, dose flexibility, or patient-support services influence prescribing decisions.

Other Competitive Companies

• Viatris: Viatris is an important international competitor through Creon outside the U.S. and is developing Creon High Dose for non-CF EPI, which has reported positive interim Phase III results; Australia's TGA also identifies Viatris as the sponsor of Creon 25,000 and 35,000, whose supply constraints currently extend through January 31, 2027 following an unexpected global increase in demand.

• Digestive Care: Digestive Care competes through FDA-approved Pertzye, a delayed-release pancrelipase therapy containing lipase, protease, and amylase for adult and pediatric EPI patients and offering another branded alternative within the established PERT category.

• Aspire Pharma: Aspire Pharma participates primarily through Crezanta in the UK, providing 10,000- and 25,000-unit gastro-resistant pancreatin formulations that add supply diversity to a market affected by constraints in several established PERT products.

• Anagram Therapeutics: Anagram Therapeutics is an emerging biotechnology competitor developing ANG003, an investigational non-porcine enzyme replacement therapy currently recruiting in a Phase II study of 113 patients with cystic-fibrosis-related EPI and using Creon as the active comparator.

• Alcresta Therapeutics: Alcresta Therapeutics occupies a differentiated enteral-nutrition niche through FDA-cleared RELiZORB, an immobilized lipase cartridge that hydrolyzes fats as formula passes through the enteral feeding circuit and is cleared for pediatric, including neonatal and infant, and adult patients.

 

Exocrine Pancreatic Insufficiency MarketReport Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.00 Billion
Revenue Forecast in 2032	USD 4.77 Billion
Overall Growth Rate	CAGR of 6.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Indication, By Route of Administration, By End User, By Distribution Channel, By Geography
By Treatment Type	Pancreatic Enzyme Replacement Therapy (PERT), Nutritional Supplements, Supportive Care, Emerging Therapies
By Indication	Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Other Indications
By Route of Administration	Oral Administration, Enteral Administration, Combination Therapy
By End User	Hospitals, Specialty Clinics, Home Care, Retail & Specialty Pharmacies
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Improved diagnosis and awareness of EPI; rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer; continued demand for pancreatic enzyme replacement therapy; development of recombinant, microbial, and synthetic enzyme treatments
Customization Option	Available upon request